New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
17:50 EDTALNY, ARWRArrowhead Research reiterates patent position
Arrowhead Research (ARWR) reaffirmed its belief that it has broad access to intellectual property required to develop ARC-520, its clinical candidate against chronic hepatitis B infection. Arrowhead does not believe there are additional unlicensed patents directed to RNAi therapeutics targeting the hepatitis B virus that affect its freedom to operate. The company signed a license agreement with Alnylam Pharmaceuticals (ALNY) in January 2012, giving it access to intellectual property that enables the discovery, development, and commercialization of an RNAi therapeutic targeting the hepatitis B virus. Arrowhead holds multiple levels of patent protection on ARC-520 including U.S. Patent Nos. 8,313,772 and 8,501,930 covering the Dynamic Polyconjugate delivery system, and U.S. Patent Application number 13/535,454 covering ARC-520ís siRNA component, which was recently allowed by the U.S. Patent and Trademark Office. Arrowhead and its legal advisors continually review the patent landscape to ensure freedom to operate and the company believes that development and commercialization of ARC-520 would not infringe patents governing RNAi therapeutics targeting the hepatitis B virus, including U.S. Patent No. 8,618,277 in the McSwiggen patent estate.
News For ARWR;ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
11:37 EDTARWROppenheimer reports 5.49% passive stake in Arrowhead
January 23, 2015
08:14 EDTARWRBridger Management reports 5.5% passive stake in Arrowhead
Subscribe for More Information
January 22, 2015
10:03 EDTARWROn the Fly: Analyst Downgrade Summary
Subscribe for More Information
09:16 EDTARWROn The Fly: Pre-market Movers
Subscribe for More Information
07:14 EDTARWRArrowhead downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
06:33 EDTARWRArrowhead downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
January 21, 2015
06:08 EDTALNYAlnylam 4.737M share Secondary priced at $95.00
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use